Formulation and delivery of itraconazole to the brain using a nanolipid carrier system

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 2117-2126

  Lim, Wei Meng ^a   Rajinikanth, Paruvathanahalli Siddalingam ^b   Mallikarjun, Chitneni ^a   Kang, Yew Beng ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b TAYLOR S UNIVERSITY   (Malaysia)

Author keywords

Brain delivery; Lipid nanoparticles; Nanostructured lipid carrier

Indexed keywords

ITRACONAZOLE; SOLID LIPID NANOPARTICLE; ANTIFUNGAL AGENT; DIACYLGLYCEROL; DIETHYLENE GLYCOL MONOETHYL ETHER; ETHYLENE GLYCOL DERIVATIVE; GLYCEROL PALMITOSTEARATE; MACROGOL DERIVATIVE; NANOCAPSULE; POLYSORBATE; SOLUTOL HS 15; STEARIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENTRAPMENT EFFICIENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; POLYDISPERSITY INDEX; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BLOOD BRAIN BARRIER; CHEMISTRY; METABOLISM; PROCEDURES; TISSUE DISTRIBUTION; ULTRASTRUCTURE;

ANIMALS; ANTIFUNGAL AGENTS; BLOOD-BRAIN BARRIER; DIGLYCERIDES; DRUG COMPOUNDING; ETHYLENE GLYCOLS; ITRACONAZOLE; MICE; NANOCAPSULES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYSORBATES; STEARIC ACIDS; TISSUE DISTRIBUTION;

EID: 84899850088     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S57565     Document Type: Article

References (45)

1. Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56(9):1257-1272.
2. Severino P, Andreani T, Macedo AS, etal. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv. 2012;2012:750891.
3. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
4. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2-3):165-196.
5. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54 Suppl 1:S131-S155.
6. Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm. 2002;242(1-2): 121-128.
7. Chen W, Gu B, Wang H, Pan J, Lu W, Hou H. Development and evaluation of novel itraconazole-loaded intravenous nanoparticles. Int J Pharm. 2008;362(1-2):133-140.
8. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother. 2005;56 Suppl 1:i33-i38.
9. De Beule K. Itraconazole: pharmacology, clinical experience and future development. Int J Antimicrob Agents. 1996;6(3):175-181.
10. Pardeike J, Weber S, Haber T, etal. Development of an itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm. 2011;419(1-2):329-338.
11. Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci. 2002; 91(6):1414-1422.
12. Akkar A, Müller RH. Intravenous itraconazole emulsions produced by SolEmuls technology. Eur J Pharm Biopharm. 2003;56(1):29-36.
13. Kim JK, Park JS, Kim CK. Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release. Int J Pharm. 2010;383(1-2):209-215.
14. Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol. 2007;3(4):573-581.
15. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today. 2007;12(1-2):54-61.
16. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173-185.
17. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev. 2007;59(6):454-477.
18. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127(2): 97-109.
19. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 2010;37(1): 48-57.
20. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3(2):90-105, 51.
21. Miyama T, Takanaga H, Matsuo H, etal. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob Agents Chemother. 1998;42(7):1738-1744.
22. Duret C, Wauthoz N, Sebti T, Vanderbist F, Amighi K. New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. Int J Nanomedicine. 2012;7: 5475-5489.
23. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 1999;59(3): 299-307.
24. Zara GP, Cavalli R, Fundarò A, Bargoni A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharmacol Res. 1999;40(3):281-286.
25. Redmann S, Charles BG. A rapid HPLC method with fluorometric detection for determination of plasma itraconazole and hydroxy-itraconazole concentrations in cystic fibrosis children with allergic bronchopulmonary aspergillosis. Biomed Chromatogr. 2006;20(4): 343-348.
26. Noack A, Hause G, Mader K. Physicochemical characterization of curcuminoid-loaded solid lipid nanoparticles. Int J Pharm. 2012;423(2): 440-451.
27. Vandamme TF, Anton N. Low-energy nanoemulsification to design veterinary controlled drug delivery devices. Int J Nanomedicine. 2010;5:867-873.
28. Baboota S, Shakeel F, Ahuja A, Ali J, Shafiq S. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. Acta Pharm. 2007;57(3):315-332.
29. Hu FQ, Yuan H, Zhang HH, Fang M. Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int J Pharm. 2002;239(1-2):121-128.
30. Vitorino C, Carvalho FA, Almeida AJ, Sousa JJ, Pais AA. The size of solid lipid nanoparticles: an interpretation from experimental design. Colloids Surf B Biointerfaces. 2011;84(1):117-130.
31. Nidhin M, Indumathy R, Sreeram K, Nair B. Synthesis of iron oxide nanoparticles of narrow size distribution on polysaccharide templates. Bulletin of Materials Science. 2008;31:93-96.
32. Freitas C, Müller RH. Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions. Int J Pharm. 1998;168(2):221-229.
33. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm 2007;328(2):191-195.
34. Helgason T, Awad TS, Kristbergsson K, McClements DJ, Weiss J. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). J Colloid Interface Sci. 2009;334(1):75-81.
35. Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces. 2011;88(1):483-489.
36. Silva AC, González-Mira E, García ML, etal. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces. 2011;86(1):158-165.
37. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95(3):627-638.
38. Lv Q, Yu A, Xi Y, etal. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm. 2009;372(1-2):191-198.
39. Abdelbary G, Fahmy RH. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech. 2009;10(1): 211-219.
40. Patel K, Padhye S, Nagarsenker M. Duloxetine HCl lipid nanoparticles: preparation, characterization, and dosage form design. AAPS PharmSciTech. 2012;13(1):125-133.
41. Xie S, Zhu L, Dong Z, etal. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: influences of fatty acids. Colloids Surf B Biointerfaces. 2011;83(2):382-387.
42. Priyanka K, Sathali AA. Preparation and evaluation of montelukast sodium loaded solid lipid nanoparticles. J Young Pharm. 2012;4(3): 129-137.
43. Madan J, Pandey RS, Jain V, Katare OP, Chandra R, Katyal A. Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine. 2013;9(4):492-503.
44. Zhang H, Yao M, Morrison RA, Chong S. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res. 2003;26(9):768-772.
45. Estella-Hermoso de Mendoza A, Préat V, Mollinedo F, Blanco-Prieto MJ. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma. J Control Release. 2011;156(3):421-426.